4Kasama S, Furuya M, Toyama T, et al. Effect of atrial natriuretic peptide on left ventrieular remodelling in patients with acute myocm'dial infarction[ J]. Eur Heart J, 2008,29 : 1485-1494.
5Rubattu S, Sciarretta S, Valenti V, et al. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases [J]. Am J Hypertens, 2008,21:733-741.
6di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk : systematic review and meta-analysis of 40 prospective studies[ J ]. Circulation, 2009,120:2177-2187.
7de Filippi CR, Christenson RH, Gottdiener JS, et al. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing[ J]. J Am Coll Cardiol,2010,55:441450.
8Smith JG, Newton-Cheh C, Almgren P, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation [ J ]. J Am Coil Cardiol, 2010,56: 17121719.
9Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community [ J ]. JAMA ,2009,302:49-57.
10Scharhag J, George K, Shave R, et al. Exercise-associated increases in cardiac biomarkers[ J]. Med Sci Sports Exerc Aug, 2008,40(8) :1408-1415.
